New Stock Issuance - New stock issuance includes 泰凯英 (code: 920020) at an issuance price of 7.50 and 超颖电子 (code: 732175) at 17.08[1] Equity Market Alerts - 上纬新材 (code: 688585) is undergoing a tender offer from September 29, 2025, to October 28, 2025[1] - 科思科技 (code: 688788) and 博瑞医药 (code: 688166) have recent announcements dated September 26, 2025, and October 10, 2025, respectively[1] - 南新制药 (code: 688189) reported severe abnormal fluctuations on October 10, 2025[1] Trading Alerts - A total of 50 stocks have trading alerts with the latest announcements on October 15, 2025, including 国光连锁 (code: 605188) and 中持股份 (code: 603903)[1] - The lowest trading alert price recorded is 1,116 for 赛恩斯 (code: 688480)[1]

Core Insights - The medical beauty sector experienced a slight increase of 0.28% on October 15, with Jinbo Biological leading the gains [1] - The Shanghai Composite Index closed at 3912.21, up 1.22%, while the Shenzhen Component Index closed at 13118.75, up 1.73% [1] Medical Beauty Sector Performance - Jinbo Biological (code: 920982) closed at 290.43, with a rise of 5.00% and a trading volume of 21,800 shares, totaling a transaction value of 628 million [1] - Huaxi Biological (code: 688363) closed at 54.72, up 1.30%, with a trading volume of 23,600 shares and a transaction value of 129 million [1] - Aimeike (code: 300896) closed at 175.15, down 0.19%, with a trading volume of 23,500 shares and a transaction value of 412 million [1] - *ST Meigu (code: 000615) closed at 3.52, down 3.03%, with a trading volume of 199,800 shares and a transaction value of 71.2 million [1] Fund Flow Analysis - The medical beauty sector saw a net outflow of 21.57 million from institutional investors and 5.26 million from retail investors, while individual investors contributed a net inflow of 26.84 million [1] - Huaxi Biological had a net inflow of 2.29 million from institutional investors, while it faced a net outflow of 5.18 million from retail investors [2] - *ST Meigu experienced a significant net outflow of 9.34 million from institutional investors, despite a net inflow of 4.25 million from retail investors [2] - Aimeike faced a net outflow of 14.53 million from institutional investors, while retail investors contributed a net inflow of 19.70 million [2]

证券代码：000615 证券简称：*ST美谷 公告编号：2025-083 奥园美谷科技股份有限公司 关于股票交易异常波动的公告 3、敬请广大投资者关注本公告风险提示内容，注意投资风险。 一、股票交易异常波动情况 奥园美谷科技股份有限公司（以下简称"公司"）股票（证券简称：*ST 美 谷，证券代码：000615）于 2025 年 10 月 13 日和 10 月 14 日连续两个交易日收 盘价格涨幅偏离值累计超过 12%，根据《深圳证券交易所交易规则》的有关规定， 属于股票交易异常波动的情况。 二、公司关注、核实情况说明 1、公司前期披露的信息不存在需要补充、更正之处。 2、公司未发现近期公共媒体报道了可能或已经对本公司股票交易价格产生 较大影响的未公开重大信息。 3、目前，除控股子公司湖北金环绿色纤维有限公司仍处于停产状态外，公 司其他子公司经营业务活动正常，内外部经营环境未发生重大变化。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别风险提示： 1、截至本公告披露日，公司已进入预重整程序，公司尚未收到法院关于受 理重整申请的相关法律文书，申请人的重整申请 ...

Core Viewpoint - The company announced that its stock experienced an abnormal fluctuation, with a cumulative increase of over 12% in closing prices over two consecutive trading days on October 13 and 14, 2025 [1] Summary by Relevant Sections - **Stock Performance** - The stock price of the company rose cumulatively by over 12% during the specified trading days, indicating significant market activity [1] - **Disclosure and Information Verification** - The company confirmed that there is no need to supplement or correct previously disclosed information, and no undisclosed significant information affecting the stock price has been found recently [1] - **Operational Status** - Other subsidiaries of the company are operating normally, and there have been no significant changes in the internal or external environment [1] - **Insider Trading Activity** - The controlling shareholder and executives did not engage in buying or selling the company's stock during the period of abnormal fluctuation [1] - **Restructuring Status** - The company is currently in a pre-restructuring phase, but there is uncertainty regarding whether it will enter the restructuring process [1]

Market Overview - The medical beauty sector experienced a decline of 0.33% on October 14, with Huaxi Biological leading the drop [1] - The Shanghai Composite Index closed at 3865.23, down 0.62%, while the Shenzhen Component Index closed at 12895.11, down 2.54% [1] Individual Stock Performance - Jinbo Biological (code: 920982) closed at 276.60, up 5.58% with a trading volume of 17,000 shares [1] - *ST Meigu (code: 000615) closed at 3.63, up 4.61% with a trading volume of 326,000 shares [1] - Aimeike (code: 300896) closed at 175.49, down 0.10% with a trading volume of 24,200 shares [1] - Huaxi Biological (code: 688363) closed at 54.02, down 1.15% with a trading volume of 33,100 shares [1] Capital Flow Analysis - The medical beauty sector saw a net inflow of 7.7391 million yuan from main funds, while retail funds experienced a net inflow of 1.0341 million yuan [1] - Speculative funds had a net outflow of 8.7732 million yuan [1] Detailed Capital Flow for Individual Stocks - Aimeike had a net outflow of 9.3340 million yuan, down 2.20% [2] - *ST Meigu experienced a net inflow of 1.1847 million yuan, up 1.03% [2] - Huaxi Biological had a significant net outflow of 10.6702 million yuan, down 5.90% [2]

Group 1 - The medical beauty sector experienced a decline of 1.92% on October 13, with Ai Meike leading the drop [1] - The Shanghai Composite Index closed at 3889.5, down 0.19%, while the Shenzhen Component Index closed at 13231.47, down 0.93% [1] - Major stocks in the medical beauty sector showed mixed performance, with *ST Meigu rising by 5.15% to a closing price of 3.47, while Ai Meike fell by 2.32% to 175.66 [1] Group 2 - The net outflow of main funds in the medical beauty sector was 75.6993 million yuan, while retail investors saw a net inflow of 48.3038 million yuan [1] - Specific fund flows for major stocks indicated that Ai Meike had a net outflow of 51.1050 million yuan, representing a decrease of 10.15% [2] - Huaxi Biological and *ST Meigu also experienced significant net outflows of 15.8278 million yuan and 8.7665 million yuan, respectively [2]

证券代码：000615 证券简称：*ST美谷 公告编号：2025-082 奥园美谷科技股份有限公司 关于预重整事项进展暨召开第一次临时债权人会议的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 重要风险提示： 1.公司已进入预重整程序，公司能否进入重整程序尚存在不确定性。 预重整程序是为了提前启动公司债权债务梳理等相关工作，提高后续重整 工作推进效率及重整可行性的程序。襄阳中院同意公司预重整，不代表法院正 式受理申请人对公司的重整申请，截至本公告披露日，公司尚未收到法院关于 受理重整申请的相关法律文书，即申请人的重整申请能否被法院受理、公司后 续能否进入重整程序均存在不确定性。敬请广大投资者注意投资风险。 重整或预重整是否成功也存在不确定性。法院决定受理预重整申请，也不 代表公司正式进入重整程序。如果公司预重整成功，法院将依法审查是否受理 重整申请，公司能否进入重整程序尚存在不确定性。敬请广大投资者注意投资 风险。 2.法院受理重整申请后，公司股票交易存在被实施退市风险警示的风险。 根据《深圳证券交易所股票上市规则（2025 年修订）》（以下简称《股票 ...

奥园美谷科技股份有限公司 预重整方案 二〇二五年十月 | | | | 十一、其他事项 34 | | --- | 释 义 除非本预重整方案中另有明确所指，下列词语的含义为： | 简称 | | 词语含义或全称 | | --- | --- | --- | | 奥园美谷/债务人/ | 指 | 奥园美谷科技股份有限公司 | | 公司 | | | | 襄阳中院 | 指 | 襄阳市中级人民法院 | | 临时管理人 | 指 | 由襄阳中院指定的奥园美谷科技股份有限公司临时 | | | | 管理人 | | 管理人 | 指 | 在襄阳中院裁定受理广州律建对奥园美谷的重整申 | | | | 请后，所指定的奥园美谷科技股份有限公司管理人 | | 奥园科星/控股股 | 指 | 深圳奥园科星投资有限公司 | | 东 | | | | 中国奥园 | 指 | 中国奥园集团股份有限公司 | | 京汉控股/前任控 | 指 | 京汉控股集团有限公司 | | 股股东 | | | | 前任控股股东及 | 指 | 前任控股股东京汉控股及其一致行动人北京合力万 | | 其一致行动人 | | 通信息咨询中心（有限合伙）、段亚娟 | | 广州律建 | 指 | ...

Market Overview - The medical beauty sector experienced a decline of 0.5% on October 10, with Jinbo Biological leading the drop [1] - The Shanghai Composite Index closed at 3897.03, down 0.94%, while the Shenzhen Component Index closed at 13355.42, down 2.7% [1] Stock Performance - The following stocks in the medical beauty sector showed varying performance: - *ST Meigu (000615)*: Closed at 3.30, down 0.30% with a trading volume of 64,200 shares [1] - Aimeike (300896): Closed at 179.84, down 0.32% with a trading volume of 27,000 shares [1] - Huaxi Biological (688363): Closed at 55.78, down 0.76% with a trading volume of 38,500 shares [1] - Jinbo Biological (920982): Closed at 267.48, down 1.95% with a trading volume of 9,733 shares [1] Capital Flow - The medical beauty sector saw a net inflow of 14.16 million yuan from main funds, while retail funds experienced a net outflow of 8.85 million yuan [1] - Detailed capital flow for specific stocks includes: - Aimeike (300896): Net outflow of 11.73 million yuan, down 2.40% [2] - *ST Meigu (000615)*: Net outflow of 1.17 million yuan, down 5.51% [2] - Huaxi Biological (688363): Net outflow of 3.72 million yuan, down 1.72% [2]

Core Viewpoint - *ST Meigu's subsidiary, Jinhua Green Fiber, failed to repay approximately 212 million yuan in debt, leading to the judicial auction of real estate assets by Jinghan Real Estate Group [1][2] Group 1: Legal and Financial Developments - On October 9, *ST Meigu announced significant litigation progress regarding its subsidiary Jinhua Green Fiber's failure to repay debt [1] - The debt originated from a fixed asset loan agreement signed in January 2020, with a repayment plan adjusted in March 2023 [1] - The Xiangyang Intermediate People's Court issued an execution notice demanding Jinhua Green Fiber repay a principal amount of 187,507,905.75 yuan, along with interest and penalties totaling approximately 27.14 million yuan by March 7, 2025 [1] Group 2: Auction Details - The real estate assets of Jinghan Real Estate will be auctioned on October 26, 2025, with a starting price of 154,380,000 yuan [2] - The auction results are uncertain, and if Jinghan Real Estate assumes the guarantee responsibility, it may reduce the liability amounts for other guarantors [2] - *ST Meigu will continue to monitor the litigation progress and disclose updates accordingly [2]